Land: Australië
Taal: Engels
Bron: Department of Health (Therapeutic Goods Administration)
Pioglitazone hydrochloride
Apotex Pty Ltd
Medicine Registered
Product Information – Australia APOTEX-Pioglitazone tablets Page 1 APOTEX-PIOGLITAZONE TABLETS NAME OF THE MEDICINE Pioglitazone hydrochloride. Chemical Name: (±)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy]phenyl]methyl]-2,4-] thiazolidinedione hydrochloride Structural Formula: Molecular Formula: C 19 H 20 N 2 O 3 S.HCl Molecular Weight: 392.91 CAS Registry Number: 112529-15-4 DESCRIPTION Pioglitazone hydrochloride is an odourless, white to off-white powder that is soluble in _N,N’_- dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water and insoluble in ether. PHARMACOLOGY Pioglitazone is an oral antidiabetic agent that acts primarily by decreasing insulin resistance. Pharmacological studies indicate that pioglitazone improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. Pioglitazone improves glycaemic control while reducing circulating insulin levels. Fasting and postprandial glycaemic control are improved in patients with type 2 diabetes mellitus. The decreased insulin resistance produced by pioglitazone results in lower blood glucose concentrations, lower plasma insulin levels and lower haemoglobin A 1c (HbA 1c ) values. PHARMACODYNAMICS Pioglitazone is a thiazolidinedione antidiabetic agent that depends on the presence of insulin for its unique mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver, resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Unlike sulfonylureas, pioglitazone is not an insulin secretagogue. Pioglitazone is a potent and highly selective agonist for peroxisome proliferator-activated receptor Lees het volledige document